NIH Director’s Wednesday Afternoon Lecture Series
More than 350 monogenic disorders of the immune system have been discovered. They are rare diseases, however, with an estimated overall frequency of one in 2,000 to 3,000 live births. This study of rare diseases is continuously providing a flow of information on how the human immune system is built; how it fights infection and avoids autoimmune, inflammatory, allergic diseases; and how it is related to some cancers. Examples will be illustrated during Dr. Fischer’s lecture as he describes recent findings from his laboratory.
Noncoding RNAs play critical roles in the metabolism of all cells. The Wolin laboratory studies how noncoding RNAs function, how cells recognize and degrade defective noncoding RNAs, and how failure to degrade these RNAs affects cell function and contributes to human disease. Their studies revealed new mechanisms by which defective RNAs are targeted for degradation and new classes of noncoding RNAs. Most recently, their work has contributed to a novel theory for how the autoimmune disease systemic lupus erythematosus may be triggered in genetically susceptible individuals.
Dr. Walsh's clinical research has focused on pharmacological issues in opioid and cocaine dependence. She has conducted studies on pharmacodynamic and pharmacokinetic characteristics of opioid treatment agents, including buprenorphine, methadone and LAAM and has evaluated potential pharmacotherapies for efficacy and safety in the treatment of cocaine dependence.
The page was last updated on Tuesday, January 23, 2018 - 8:42am